Skip to content
PubMed This is a summary of 11 peer-reviewed journal articles Updated
Hematology

Building Your Care Team and Preparing for Visits

At a Glance

People with congenital dyserythropoietic anemia type I benefit from a coordinated rare-anemia care team and organized records. Bring genetic, bone marrow, transfusion, medication, imaging, vaccination, and family-history information so specialists can plan iron monitoring and treatment.

Managing an ultra-rare condition like Congenital Dyserythropoietic Anemia Type I (CDA I) requires more than just a standard hematologist. Because the condition affects multiple organ systems—from the bone marrow to the heart and endocrine glands—the most successful care often comes from a multidisciplinary team coordinated by a specialist in rare anemias [1][2].

Building Your Multidisciplinary Team

A “holistic” approach is recommended because the complications of CDA I often intersect [1]. Your core team may include:

  • Rare Anemia Hematologist: This is your “quarterback.” You should look for a clinician who regularly manages rare, non-spherocytic hemolytic or dyserythropoietic anemias. They can coordinate care and refer you to other specialists as needed. Ask if they participate in networks like the North American CDA Registry [2][1].
  • Geneticist or Genetic Counselor: Essential for interpreting the specific mutations in CDAN1 or CDIN1 and discussing inheritance with your family [3][1].
  • Endocrinologist: They monitor for “iron-related” endocrine issues, such as low bone density (osteoporosis), thyroid dysfunction, and diabetes [4][5].
  • Cardiologist: Since pulmonary hypertension is a known risk in adults, a cardiologist with experience in high-output heart failure or pulmonary pressure is vital when symptoms or screens indicate it [5][6].
  • Hepatologist or Gastroenterologist: They manage liver iron levels and the high incidence of gallstones associated with the breakdown of red blood cells [5].

Vetting Your Clinical Team

When meeting a new doctor, you are interviewing them to see if they have the specific expertise needed for CDA I. A knowledgeable clinician should be able to explain their written plan for monitoring iron independent of transfusions, as iron can build up with age even in “non-transfused” patients [7][4].

If you are considering treatments like pegylated interferon-alpha, ask how they intend to track not just your hemoglobin, but also your patient-reported outcomes—such as energy levels and treatment side effects [8]. A provider who only focuses on blood counts may miss the “human” side of living with chronic anemia. Furthermore, if your case is severe, ask if they have a relationship with a transplant hematologist to discuss the risks and benefits of a stem cell transplant before major complications develop [9][5].

The First Appointment Records Checklist

Because CDA I is so rare, you should not assume a new office has your complete history. Bringing these specific records to bring can significantly shorten the time to a correct treatment plan:

  • Complete Genetic Reports: Not just a summary, but the full lab report showing the exact variants in CDAN1 or CDIN1 and whether carrier status was confirmed in your parents [3][1].
  • Bone Marrow Records: If you have had a biopsy, bring the original pathology report and any electron microscopy (EM) findings (such as the “Swiss cheese” chromatin) [10].
  • Transfusion History: A log of dates, the number of units received, and how long you went between treatments [7][11].
  • Current Medicines and Chelation History: A complete list of current medicines, doses, and any history of chelation therapy.
  • Vaccination Status: Especially critical if you have had a splenectomy.
  • Imaging Results: Printed reports (or a CD) of liver and cardiac MRI T2* studies, as well as recent echocardiograms or abdominal ultrasounds [7][5].
  • Family History: A three-generation family tree showing anyone with similar symptoms or known anemia [1].

Bringing these materials ensures that your specialist spends the appointment discussing your future care rather than hunting for your past records.

Common questions in this guide

Which specialists should I include in a CDA I care team?
A rare-anemia hematologist can coordinate care, with a geneticist or genetic counselor to interpret CDAN1 or CDIN1 results. Depending on your needs, an endocrinologist, cardiologist, and hepatologist or gastroenterologist may monitor hormone, heart, liver, and gallstone-related concerns.
Do I need iron monitoring if I have never had regular transfusions?
Yes. Iron can build up with age even in people who are not receiving transfusions, so ask about a written monitoring plan and whether liver MRI T2* or other testing is appropriate.
What records should I bring to my first CDA I specialist visit?
Bring full genetic reports, bone marrow pathology and electron microscopy findings, transfusion history, current medicines, chelation history, vaccination status, liver and cardiac MRI T2* reports, echocardiograms or abdominal ultrasounds, and a three-generation family history. These records help the team understand prior testing and plan care.
How should success be measured if I start pegylated interferon-alpha?
Ask your clinician to define a hemoglobin target and track outcomes beyond blood counts, such as energy, daily functioning, and treatment side effects. The goals should reflect both laboratory results and how you feel.
When should stem cell transplant be discussed in CDA I?
If CDA I is severe, ask whether a transplant hematologist should review the risks and potential benefits before major complications develop. Transplant decisions are individualized and should be made with specialists who know your history.
How is CDA I checked against conditions that look similar?
Specialists may review full genetic testing for CDAN1 or CDIN1, bone marrow pathology and electron microscopy findings, and your clinical history. They may also compare the findings with other causes of anemia, such as pyruvate kinase deficiency, to avoid treating a similar-looking condition as CDA I.

Get notified when new evidence is published on Congenital dyserythropoietic anemia type I.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (11)
  1. 1

    The pathogenesis, diagnosis and management of congenital dyserythropoietic anaemia type I.

    Roy NBA, Babbs C

    British journal of haematology 2019; (185(3)):436-449 doi:10.1111/bjh.15817.

    PMID: 30836435
  2. 2

    Congenital dyserythropoietic anemia type I: First report from the Congenital Dyserythropoietic Anemia Registry of North America (CDAR).

    Niss O, Lorsbach RB, Berger M, et al.

    Blood cells, molecules & diseases 2021; (87()):102534 doi:10.1016/j.bcmd.2020.102534.

    PMID: 33401150
  3. 3

    A novel homozygous C15ORF41 variant (c.251T > A; p.Val84Glu) causing congenital dyserythropoietic anemia type Ib in an Indian patient: molecular and structural evidence.

    Kamble P, Dongerdiye R, More T, et al.

    Molecular biology reports 2026; (53(1)).

    PMID: 42397456
  4. 4

    Endocrine Complications in Patients with Congenital Dyserythropoietic Anemia: A Single-Center Cohort Study.

    Gursoy G, Ünlütürk U, Karabulut E, Unal S

    Hemoglobin 2026; 1-9 doi:10.1080/03630269.2026.2729185.

    PMID: 42817261
  5. 5

    Morbidity and mortality of adult patients with congenital dyserythropoietic anemia type I.

    Shalev H, Al-Athamen K, Levi I, et al.

    European journal of haematology 2017; (98(1)):13-18 doi:10.1111/ejh.12778.

    PMID: 27206021
  6. 6

    Prevalence of left ventricular hypertrabeculation/noncompaction among patients with congenital dyserythropoietic anemia Type 1 (CDA1).

    Abramovich-Yoffe H, Shalev A, Barrett O, et al.

    International journal of cardiology 2020; (317()):96-102 doi:10.1016/j.ijcard.2020.05.092.

    PMID: 32512057
  7. 7

    Hepatic and cardiac iron load as determined by MRI T2* in patients with congenital dyserythropoietic anemia type I.

    Asleh M, Levitas A, Daniel S, et al.

    Annals of hematology 2020; (99(11)):2507-2512 doi:10.1007/s00277-020-04263-4.

    PMID: 32918595
  8. 8

    Using Patient Feedback to Improve Treatment Outcomes for Patients with Congenital Dyserythropoietic Anaemia Type I Receiving Interferon Therapy.

    Frey K, Brolih S, Scott C, et al.

    Journal of clinical medicine 2026; (15(2)) doi:10.3390/jcm15020901.

    PMID: 41598837
  9. 9

    Hematopoietic Cell Transplantation for Congenital Dyserythropoietic Anemia: A Report from the Pediatric Transplant and Cellular Therapy Consortium.

    Rangarajan HG, Stanek JR, Abdel-Azim H, et al.

    Transplantation and cellular therapy 2022; (28(6)):329.e1-329.e9 doi:10.1016/j.jtct.2022.03.007.

    PMID: 35288346
  10. 10

    Morphological features of congenital dyserythropoietic anemia type I: The role of electron microscopy in diagnosis.

    Resnitzky P, Shaft D, Shalev H, et al.

    European journal of haematology 2017; (99(4)):366-371 doi:10.1111/ejh.12931.

    PMID: 28755517
  11. 11

    Hematopoietic Stem Cell Transplantation in Congenital Dyserythropetic Anemia Type II: A Case Report and Review of the Literature.

    Uygun V, Russo R, Karasu G, et al.

    Journal of pediatric hematology/oncology 2020; (42(6)):e507-e510 doi:10.1097/MPH.0000000000001612.

    PMID: 31593005

This page is for informational purposes only and does not constitute medical advice. A rare-anemia hematologist and your multidisciplinary team should interpret your CDA I records and tailor monitoring and treatment to your needs.